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Objectives This study sought to assess the efficacy of niacin for reducing cardiovascular disease (CVD) events, as indicated
by the aggregate body of clinical trial evidence including data from the recently published AIM-HIGH (Athero-
thrombosis Intervention in Metabolic Syndrome with Low HDL/High Triglycerides: Impact on Global Health Out-
comes) trial.
Background Previously available randomized clinical trial data assessing the clinical efficacy of niacin has been challenged
by results from AIM-HIGH, which failed to demonstrate a reduction in CVD event incidence in patients with estab-
lished CVD treated with niacin as an adjunct to intensive simvastatin therapy.
Methods Clinical trials of niacin, alone or combined with other lipid-altering therapy, were identified via MEDLINE. Odds
ratios (ORs) for CVD endpoints were calculated with a random-effects meta-analyses. Meta-regression modeled
the relationship of differences in on-treatment high-density lipoprotein cholesterol with the magnitude of effect
of niacin on CVD events.
Results Eleven eligible trials including 9,959 subjects were identified. Niacin use was associated with a significant reduc-
tion in the composite endpoints of any CVD event (OR: 0.66; 95% confidence interval [CI]: 0.49 to 0.89; p  0.007)
and major coronary heart disease event (OR: 0.75; 95% CI: 0.59 to 0.96; p 0.02). No significant association was
observed between niacin therapy and stroke incidence (OR: 0.88; 95% CI: 0.5 to 1.54; p 0.65). The magnitude of
on-treatment high-density lipoprotein cholesterol difference between treatment arms was not significantly associated
with the magnitude of the effect of niacin on outcomes.
Conclusions The consensus perspective derived from available clinical data supports that niacin reduces CVD events and,
further, that this may occur through a mechanism not reflected by changes in high-density lipoprotein choles-
terol concentration. (J Am Coll Cardiol 2013;61:440–6) © 2013 by the American College of Cardiology
Foundation
Published by Elsevier Inc. http://dx.doi.org/10.1016/j.jacc.2012.10.030C
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LExtensive epidemiological data have established elevated
low-density lipoprotein cholesterol (LDL-C) as a major
predictor of cardiovascular disease (CVD) risk. Current
national CVD prevention guidelines strongly reflect this
observation, focusing on lipid intervention strategies pri-
marily targeting LDL-C (1–3). This approach is supported
y considerable evidence derived from randomized con-
rolled trials (RCTs) of 3-hydroxy-3-methylglutaryl coen-
yme A reductase inhibitor (statin) therapy demonstrating a
eduction in CVD event rate proportional to the achieved
bsolute reduction in LDL-C (4). Recent analyses indicate
hat this quantitative relationship between LDL-C and
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laccepted October 28, 2012.VD risk persists throughout even very low LDL-C con-
entrations, suggesting that as many as 40% of CVD events
ay be prevented by intensive statin therapy (5,6). While
alidating the incremental benefit of aggressive statin use,
owever, a review of recent RCTs revealed a substantial
VD event rate in those treated to achieve even the most
tringent LDL-C targets (7–11). Recognition of this sizable
esidual risk has intensified efforts to identify novel thera-
eutic interventions.
Current understanding of the pathophysiology underly-
ng atherosclerosis suggests a complex, multifactorial mech-
nism, only partially modulated by the most prominent
arget of statins, LDL-C. Niacin, a broad-spectrum lipid-
egulating agent, has been shown to exert multiple favorable
ffects on cholesterol metabolism, including reduction of
otal cholesterol, triglycerides, very low-density lipoprotein,
DL-C, lipoprotein (a), and augmentation of high-density
ipoprotein cholesterol (HDL-C) (12,13). It has also been
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atheroprotective effects (13,14). As such, niacin has been in
clinical use for many decades for the prevention of CVD.
Previous clinical trials evaluating the efficacy of niacin
treatment in cardiovascular outcomes yielded promising
results. The Coronary Drug Project, a randomized, placebo-
controlled secondary prevention trial, demonstrated a sig-
nificant reduction in CVD events in the niacin intervention
arm compared with that in placebo-treated subjects (15).
Subsequent trials examining the combined effect of niacin
added to statin therapy reported similar benefit with respect
to various surrogate endpoints (16–21).
These somewhat limited empirical data supporting nia-
cin’s clinical efficacy have been challenged by the recently
published results of the AIM-HIGH (Atherothrombosis
Intervention in Metabolic Syndrome with Low HDL/High
Triglycerides: Impact on Global Health Outcomes trial)
(22). Cosponsored by the National Heart, Lung, and Blood
Institute, AIM-HIGH was designed to evaluate the addi-
tion of extended-release niacin to intensive statin therapy in
patients with established CVD and atherogenic dyslipide-
mia (characterized by low HDL-C, elevated triglycerides,
and small, dense LDL-C), compared with statin use alone.
The study was stopped prematurely after an interim analysis
revealed futility with respect to the primary clinical endpoint
and a trend toward increased stroke incidence in niacin-
treated subjects.
We sought to assess the impact of these results on the
collective body of evidence evaluating the clinical efficacy of
niacin. Described here is a systematic analysis of niacin
RCTs that report CVD outcome data.
Methods
Trial inclusion. A MEDLINE search identified trials of
niacin therapy, alone or in conjunction with additional
lipid-altering interventions, published in the English lan-
guage literature between January 1966 and December 2011.
Eligible studies were of randomized, controlled design
reporting clinical CVD event data with a minimum of 6
months of follow-up. The electronic search strategy in-
cluded the terms niacin, niaspan, nicotinic acid, acipamox,
vitamin B3, and vitamin pp. Citations were limited using
the terms human, English language, and randomized con-
trolled trial. To ensure a comprehensive identification of
appropriate trials, we conducted a supplemental manual
review of citations from all eligible studies and relevant
systematic analyses (23,24).
Data extraction and quality assessment. All citations
were screened at the abstract level, and full articles of
eligible trials were independently reviewed. The follow-
ing variables were collected from the published article of
each eligible study as available: baseline demographic
characteristics of study participants (sample size, age, sex,
diabetes, smoking status, and body mass index); baseline
and on-treatment serum HDL-C, LDL-C, total cholesterol,and triglyceride levels; and the oc-
currence of clinical CVD events
(cardiac death, nonfatal myocar-
dial infarction, hospitalization for
acute coronary syndrome, stroke,
or revascularization). In the event
of multiple active treatment arms,
analysis was limited to the 2
groups from each trial least con-
founded with respect to niacin use.
This was achieved by exclusion of
subjects receiving non-niacin ther-
apy in the intervention arms of 2
trials (15,25), those assigned to
treatment with antioxidant vita-
mins in another (16), and the ni-
acin monotherapy arm of a fourth study in which control
subjects received combination therapy with ezetimibe and
simvastatin (26).
The quality of individual trial design and execution was
assessed via evaluation of randomization methods, conceal-
ment of treatment allocation, and description of withdrawals
and dropouts, which was quantified using Jadad’s scale (27).
Analysis. Our pre-specified primary analysis estimated the
summary effect of niacin, as either monotherapy or an
adjunctive lipid-modifying intervention, on the composite
endpoint of any CVD event (defined as cardiac death, nonfatal
myocardial infarction, hospitalization for acute coronary syn-
drome, stroke, or revascularization procedure). Two secondary
endpoints were also analyzed: major coronary heart disease
(CHD) event, (defined as nonfatal myocardial infarction or
cardiac death), and stroke (ischemic or hemorrhagic). A
pre-specified subgroup analysis evaluated the effect of niacin as
an adjunct to statin therapy on each of the primary and
secondary clinical outcome measures (16,17,19,22,26). An
additional analysis was performed limited to trials in which the
lipid-modifying intervention differed only with respect to the
presence of niacin therapy between treatment and control arms
(15,17,22,26).
An exploratory meta-regression analysis was performed
examining a potential association between the difference in
HDL-C concentration between trial arms with the calcu-
lated effect size of each respective trial for the primary
endpoint of any CVD event.
Statistical methods. Measures of effect size with respect to
the prespecified clinical endpoints for each included study
are presented as odds ratios (ORs). The I2 statistic was
calculated to quantify the proportion of inconsistency ob-
served across trials. Given the variation in baseline popula-
tion characteristics and lipid-modifying regimens used
within the included studies, a random-effects model (Der-
Simonian and Laird) was chosen to estimate the pooled
effect of all trials for each prespecified clinical endpoint. To
determine the extent to which inclusion of the 2 largest
Abbreviations
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disease
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disease
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lipoprotein cholesterol
LDL-C  low-density
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Niacin in Cardiovascular Prevention January 29, 2013:440–6were performed excluding the Coronary Drug Project (15)
r AIM-HIGH (22).
Exploratory analyses designed to assess the role of HDL-
as a predictor of between-study variation in clinical outcome
as limited to the primary composite endpoint of any CVD
vent due to constraints in requisite data availability. The
atural log-transformed OR was modeled as a linear function
f the trial-specific on-treatment difference in HDL-C con-
entration between study arms via inverse variance-weighted
andom-effects meta-regression for the outcome of interest.
Statistical analyses were performed using the Review
anager (RevMan) software package version 5.1 (The
ordic Cochrane Centre, Copenhagen, Denmark; the Co-
hrane Collaboration, 2011) and SPSS 19.0 (SPSS, Inc.,
hicago, Illinois). The threshold for statistical significance
as set at the 2-tailed alpha level of 0.05.
esults
ur search strategy yielded 560 citations that were screened
t the abstract level, of which 173 were retrieved for detailed
valuation. On review of full-text articles, 11 trials were
eemed eligible according to the aforementioned criteria for
nclusion in the present analysis. There was a total of 4,365
ubjects allocated to receive niacin intervention and 5,596
ubjects allocated to the respective control arms of included
rials. The mean duration of follow-up was 2.7 years (SD
.7 years). Study quality, as quantified by the Jadad scale was
3 for each eligible trial. Of the 11 trials included in the
rimary meta-analysis, 8 were conducted in a double-blind
ashion (15–17,22,25,26,28,29). Baseline demographic and
linical characteristics of study participations are provided in
able 1.
eta-analysis. Among selected trials, 1 was excluded from
nalysis of major CHD event (25) and 4 from that of stroke
ncidence (19,25,28,29,31) due to the absence of reported
vents for these outcomes during the period of observation.
n a summary analysis of all trials, the primary composite
ndpoint of any CVD event was significantly less frequent
n niacin-treated patients compared with controls (OR:
.66; 95% confidence interval [CI]: 0.49 to 0.89; p 0.007;
2  59%) (Fig. 1). A significant response to niacin
treatment was also demonstrated in a similar analysis
performed with respect to the secondary endpoint of major
CHD events (OR: 0.75; 95% CI: 0.59 to 0.96; p  0.02;
I2  31%) (Fig. 2). There was no significant difference in
stroke risk between subjects allocated to niacin treatment
compared with controls (OR: 0.88; 95% CI: 0.5 to 1.54;
p  0.65; I2  41%) (Fig. 3). Pooled effect estimates were
not significantly changed for any clinical endpoint on
sensitivity analysis excluding the Coronary Drug Project,
the largest single trial (15) (Online Appendix A). Sensitivity
analysis excluding AIM-HIGH also resulted in a niacin-
associated improvement in outcomes including a significant
decrease in stroke incidence (Online Appendix B). Tr
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e
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January 29, 2013:440–6 Niacin in Cardiovascular PreventionIncluding only those trials evaluating the efficacy of niacin
in conjunction with statin use (16,17,19,22,26), a significant
treatment effect was observed on the composite endpoint of
any CVD event (OR: 0.31; 95% CI: 0.1 to 0.97; p  0.04).
No significant effect of niacin was observed on the outcomes
of major CHD event or stroke (data not shown).
Analyses limited to trials in which treatment and control
arms differed only with respect to the presence of niacin
therapy (15,17,22,26) revealed a significantly decreased
frequency of CHD events in niacin-treated patients (OR:
0.86; 95% CI: 0.75 to 0.98; p  0.03), but no significant
effect on all CVD events or stroke (data not shown).
Meta-regression. Of the 11 trials selected for the principal
analysis reporting outcome data for the primary composite
endpoint of any CVD event, 9 provided baseline and
on-treatment measures of HDL-C and were thus included
in the pre-specified secondary random-effects meta-
regression analysis (16,17,19,22,25,26,28–31). No signifi-
cant association was found between the magnitude of the
difference between treatment arms in on-treatment HDL-C
and the natural log-adjusted OR for any CVD event
incidence (Beta  0.0125, p  0.86) (Fig. 4).
Figure 1 Effect of Niacin Therapy on the Occurrence of Any Ca
Random-effects odds ratio shown. Horizontal lines represent 95% confidence inte
Figure 2 Effect of Niacin Therapy on the Occurrence of Major C
Random-effects odds ratio shown. Horizontal lines represent 95% confidence inteDiscussion
Despite clear efficacy demonstrated by multiple clinical
endpoint–driven studies, increasing appreciation of the
considerable CVD risk that persists despite intensive statin
therapy (4,5,32) has heightened interest in alternative ther-
apeutic interventions. The consensus perspective derived
from previously available data had suggested that niacin
could be an effective agent in CVD risk prevention (23,24).
Although clinical outcome data supporting its benefits
largely predate the advent of statins, several recent trials
showed niacin to be an effective adjunct to statin therapy
with respect to surrogate measures of atherosclerosis pro-
gression (16–21). Contrasting evidence provided by results
of the AIM-HIGH trial (22) recently called into question
the appropriate role of niacin in clinical practice. The
present study, taking in aggregate the cumulative body of
relevant empirical clinical data, continues to support that
niacin is an effective agent to reduce CVD risk.
In the present meta-analysis including a total of 9,959
subjects derived predominantly from secondary prevention
trials, allocation to niacin treatment yielded relative odds
ascular Disease Event
Is).
vents
Is).rdiov
rvals (CHD E
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Niacin in Cardiovascular Prevention January 29, 2013:440–6reductions of 34% (p  0.007) and 25% (p  0.02) for the
espective endpoints of any CVD event and major CHD
vent. Furthermore, a significant treatment effect remained
n analysis limited to those trials evaluating the effect of
iacin in combination with statin therapy for the largest
omposite clinical endpoint of any CVD event. Placing
hese findings in context, the Cholesterol Treatment Trial-
sts’ Collaboration recently reported 22% and 27% reduc-
ions in comparable clinical endpoints in statin-treated
articipants compared with a control population in a meta-
nalysis of 21 trials including 129,526 subjects (5).
While serving to place the recent results of AIM-HIGH
n context with the total body of clinical trial evidence, the
urrent analysis challenges prevalent notions surrounding
Figure 3 Effect of Niacin Therapy on the Occurrence of Stroke
Random effects odds ratio shown. Horizontal lines represent 95% confidence inte
Figure 4 Association Between On-Treatment HDL-C Difference
Between Study Arms and Any CVD Event
Random-effects meta-regression analysis depicting the relationship between
the log-adjusted odds ratio for the composite endpoint of any cardiovascular
disease (CVD) event and the difference in on-treatment high-density lipoprotein
cholesterol (HDL-C) concentration between niacin treatment and control arms.
Each included study is represented by a circle, the size of which is proportional
to its respective weight in the analysis.he mechanism underlying the treatment effect of niacin.
idely recognized as the most potent currently available
odulator of HDL-C, the potential benefit of niacin in
itigating CVD risk is often attributed to its impact on this
arget. The rationale for this hypothesis is derived from
xtensive epidemiological data establishing baseline low
DL-C as an independent marker of CVD risk (33–37). It
s important to consider, however, that the pharmacological
ffects of niacin extend well beyond augmentation of
DL-C concentration. In the current study, meta-
egression failed to demonstrate an association between
n-treatment differences in HDL-C concentration and
iacin-mediated improvement of outcomes. There are sev-
ral ways in which this finding can be interpreted. One
ossibility is that the clinical efficacy of niacin may still
esult from its lipid effects, but that these are not captured in
he standard lipid measurements reported in clinical trials.
or example, niacin reduces lipoprotein (a) and exerts
resumably favorable effects on both HDL-C and LDL-C
article size distribution, not reflected by typical lipoprotein
nalysis nor assessed in the current study (38). It is also
ossible that niacin’s clinical benefit may result not from its
ipid effects, but rather may be contingent on any of its
everal reported pleiotropic properties. As such, consider-
tion should also be paid to expanding data delineating the
arious nonlipoprotein-mediated effects of niacin as a means
o explain its efficacy. Niacin has been documented to
xhibit anti-inflammatory properties as evidenced by a
eduction in lipoprotein-associated phospholipase A2 and
C-reactive protein (38), suppress pro-atherogenic chemo-
kines (39), and augment serum concentration of the ather-
protective hormone adiponectin (40,41), each of which
could confer cardiovascular protection.
That niacin may attenuate atherosclerotic progression
and vascular inflammation via measures independent of its
effect on lipoprotein concentration is supported by observa-
tions in several animal models (42–44). Lukasova et al. (43)
recently demonstrated a niacin-associated antiatheroscle-
rotic effect in LDL-receptor knockout mice not accompa-
CIs).rvals (nied by change in either HDL-C or total cholesterol.
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January 29, 2013:440–6 Niacin in Cardiovascular PreventionSimilarly, regression of atherosclerosis burden and plaque
stabilization have been documented in apolipoprotein
E–deficient mice on niacin administration absent a signif-
icant change in lipid profile (44). Indeed, emerging evidence
ontesting the uniform viability of HDL-C as both a
herapeutic target and surrogate marker of CVD risk sug-
ests that attribution of niacin’s clinical efficacy to augmen-
ation of serum HDL-C may be misdirected. The dal-
UTCOMES trial (NCT00658515), designed to evaluate
he efficacy of cholesterol ester transfer protein inhibition by
alcetrapib as an adjunct to existing standard of care in
econdary prevention of CVD was recently halted due to a
ack of clinically meaningful benefit despite increasing
DL-C in excess of 25% during phase II clinical trials
45,46). Moreover, Mendelian randomization analyses
ailed to establish a relationship between genetic polymor-
hisms associated with HDL-C levels and CHD event
ncidence (47). The present findings thus reinforce the
otential significance of niacin’s various pleiotropic actions and
autions against defining its clinical utility to be exclusively
ependent on the validity of the HDL-C hypothesis.
Preliminary reports from AIM-HIGH raised substantial
oncern over the safety of niacin. Interim analysis of
schemic stroke in the treatment arm of AIM-HIGH
emonstrated a trend toward increased risk, which impor-
antly failed to reach statistical significance in the final
ntention-to-treat analysis. Of note, 8 patients included in
he AIM-HIGH analysis, all of whom were assigned to
iacin treatment, sustained a stroke between 2 months and
years after discontinuation of the study drug (22). Al-
hough not definitive, the absence of a similar association in
he present analysis is both reassuring and consistent with
hat expected based on previous evidence (15).
Importantly, decades of clinical data have confirmed the
verall safety of niacin therapy, particularly that of the
rescription version used in the AIM-HIGH study. A
ecent review of the U.S. Food and Drug Administration’s
FDA) Adverse Event Reporting System found prescription
iacin to be associated with a lower rate of serious adverse
vents (defined as resulting in hospitalization or death),
epatotoxicity, and rhabdomyolysis compared with that of
everal other commonly used lipid-altering drugs including
imvastatin, pravastatin, atorvastatin, gemfibrozil, and feno-
brate (48). Furthermore, the safety profile of niacin-statin
ombination therapy has been found comparable to that of
ither drug alone (48–50).
tudy limitations. It is important to note that the present
ndings are not without limitation. The use of trial-level
ata as opposed to patient-level data represents a limitation,
nd access to individual patient data would allow a more
obust analysis. Additionally, although clinical outcomes were
djudicated in individual trials, standardized adjudication was
ot possible across all included RCTs. Moreover, although
andom effects were assumed in the present statistical analysis,
he mild to moderate variation across studies reflected in
eterogeneity testing cannot be disregarded and represents aotential for confounding by factors such as between-trial
ariation in population characteristics, dosing, and comparators
including variable regimens of combination lipid-modifying
herapy). The limited available clinical data largely confined to
mall trials of niacin therapy may also subject the present
nalysis to potential publication bias, which should be consid-
red when interpreting the reported findings. Finally, although
hought provoking, results of the meta-regression reflect an
bservation across trials and may be subject to confounding by
ndividual trial and patient characteristics not captured in the
urrent analysis.
onclusions
lthough potentially indicative of limited efficacy in select
atients, the recently published findings of AIM-HIGH are
nsufficient to alter the aggregate available data supporting
he clinical efficacy of niacin therapy as a means to reduce
VD risk. The present analysis demonstrates the summary
ffect of niacin across a broad clinical population to confer
theroprotection and cautions against the extension of
ecent isolated findings to substantially alter overall clinical
ractice. These results thus underscore the need for further
nalysis, including that offered by the ongoing HPS2-
HRIVE (Heart Protection Study 2 Treatment of HDL to
educe the Incidence of Vascular Events) trial, to more
learly define the role of niacin in current practice.
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